NOVONORM 1MG TABLET contains Repaglinide which belongs to the group of medicines called Antidiabetics. It is used to treat type 2 diabetes as an adjunct to diet and exercise. Type 2 diabetes is a disease condition in which the pancreas does not make enough insulin to control sugar in the body or the body does not react well to insulin that is produced thus, leading to high blood glucose levels.
The symptoms of high blood sugar levels are feeling thirsty, increased urination, dry skin, and a dry mouth. While being treated with NOVONORM 1MG TABLET, your doctor may advise you to make some lifestyle changes, such as having a balanced diet, getting good sleep, exercising, etc. Before starting the treatments with NOVONORM 1MG TABLET, your doctor would want you to take some diagnostic tests.
NOVONORM 1MG TABLET is not recommended in patients who have severe liver disease, diabetes type 1, or diabetic ketoacidosis. Patients who have moderate liver diseases, or kidney problems, or are about to have surgery should take NOVONORM 1MG TABLET with caution.
NOVONORM 1MG TABLET should not be taken by pregnant or breastfeeding women or children below 18 years of age. It is also not recommended for use in adults over 75 years of age. The most common side effects of NOVONORM 1MG TABLET are hypoglycaemia, stomach pain, and diarrhoea. Talk to your doctor if any of your symptoms get worse or don’t improve.
NOVONORM 1MG TABLET helps in reducing blood sugar levels by acting on specific cells (beta cells) present in the pancreas and increasing the release of insulin. Insulin is responsible for bringing blood sugar levels down.
Take NOVONORM 1MG TABLET as advised by your physician. Swallow the medicine with a glass of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
Stop taking NOVONORM 1MG TABLET if you experience any of the following side effects and talk to your doctor immediately:
Drink lots of fluids, such as water or fruit juice to keep yourself hydrated. Do not consume any medicine on your own without consulting your doctor.
Try to rest and relax. Eat and drink slowly or try to have smaller and more frequent meals. Keep a heating pad on your stomach. If the symptom does not improve, contact your doctor.
NOVONORM 1MG TABLET is not recommended for use in pregnant women. Consult your doctor before taking it.
NOVONORM 1MG TABLET is not recommended for use in breastfeeding women. Consult your doctor before taking it.
Do not drive or use machinery after taking NOVONORM 1MG TABLET if you feel a hypoglycaemic state. Consult your doctor for advice.
Avoid the consumption of alcohol as it may change the ability of NOVONORM 1MG TABLET to lower blood sugar. Watch out for hypoglycaemia.
NOVONORM 1MG TABLET should be taken with caution in patients with kidney disease. Consult your doctor before taking it.
NOVONORM 1MG TABLET is generally not recommended in patients with severe liver disease. It should be used with caution in patients with moderate liver disease. Consult your doctor before taking it.
Do not take NOVONORM 1MG TABLET if you are allergic to Repaglinide.
NOVONORM 1MG TABLET is generally not recommended for use in children and adolescents (under 18 years of age). Consult your doctor before taking it.
NOVONORM 1MG TABLET should be used with caution in elderly patients above 75 years of age. Consult your doctor before taking it.
NOVONORM 1MG TABLET is not recommended for use if you:
Before taking NOVONORM 1MG TABLET inform your doctor if you:
A. Drug-Drug Interactions:
Overdosage:
If you or anyone else accidentally take too much of NOVONORM 1MG TABLET it can lead to hypoglycaemia. Inform your doctor immediately or visit the nearby hospital. Symptoms of overdosage of NOVONORM 1MG TABLET are cold sweat, cool pale skin, headache, fast heartbeat, nausea, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious and confused, and difficulty in concentrating.
Drug | : | Repaglinide |
Pharmacological Category | : | Meglitinides |
Therapeutic Indication | : | Diabetes mellitus type 2 |
Dosage Forms | : | Tablet |
Q: Can NOVONORM 1MG TABLET be used alone to treat diabetes mellitus type 2?
A: No. NOVONORM 1MG TABLET is used in the treatment of diabetes mellitus type 2 or non-insulin-dependent diabetes mellitus as an adjunct to diet or when diet and other sugar-lowering medications are not working enough. Your doctor will be able to better understand your condition and treat it accordingly.
Q: Is an overdose of NOVONORM 1MG TABLET likely to cause hypoglycemia (abnormally low blood sugar)?
A: Yes. An overdose of NOVONORM 1MG TABLET can cause hypoglycemia. Symptoms of overdosage of NOVONORM 1MG TABLET are cold sweat, cool pale skin, headache, fast heartbeat, drowsiness, unusual tiredness and weakness, nausea, feeling very hungry, temporary changes in vision, nervousness or tremor, feeling anxious and confusion, and difficulty concentrating. If you or anyone else happens to have an overdose of NOVONORM 1MG TABLET, you should contact your doctor immediately.
Q: What should I do if I forget to take a dose of NOVONORM 1MG TABLET?
A: If you forgot to take a dose of NOVONORM 1MG TABLET, then do not take the missed dose between meals. Wait until your next scheduled dose and meal and continue taking your medicine as normal. Do not take a double dose of NOVONORM 1MG TABLET to make up for a forgotten dose. Consult your doctor for advice.
Q: Can I stop taking NOVONORM 1MG TABLET on my own?
A: No. You should not stop taking NOVONORM 1MG TABLET without the advice of the doctor. If you do so, the desired effect may not be achieved, and your blood sugar level can rise again.
Q: Can NOVONORM 1MG TABLET be used in children and adolescents?
A: No, NOVONORM 1MG TABLET is not recommended for use in children and adolescents (below 18 years of age). Consult your doctor for advice.
1. KD Tripathi. Insulin, Oral Hypoglycaemic Drugs and Glucagon. Essentials of medical pharmacology. Seventh edition. 2013. Page – 273.
2. Zara Milner, Hossein Akhondi. Repaglinide. NIH National Library of Medicine, National center for biotechnology information. Jan 2022. [Accessed on 25th May 2022] https://www.ncbi.nlm.nih.gov/books/NBK559305/#article-93347.s3
3. Accord Healthcare. Electronic Medicines Compendium (EMC). [Revised in Jan 2019] [Accessed on 25th April 2022] https://www.medicines.org.uk/emc/files/pil.4629.pdf
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.